Fatty Acid Supplementation in Toddlers Born Preterm and Attention and Autism Outcomes at 8–10 Years: Omega Tots Randomized Controlled Trial Long-Term Follow-Up

Abstract Purpose Children born preterm are at increased likelihood of autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD). We examined whether 6 months of daily dietary docosahexaenoic acid (DHA) + arachidonic acid (AA) supplementation at age 1-year reduced attention problems and likelihood of ADHD and ASD diagnoses in children born preterm. Methods In the Omega Tots randomized placebo-controlled trial, children born at <35 weeks’ gestation received daily DHA (200 mg) + AA (200 mg) or placebo (400 mg corn oil) at 10–16 months’ corrected age. This long-term follow-up assessed outcomes at 8.5–10.5 years. Outcomes included parent- and teacher-rated attention problems, performance on the Flanker Inhibitory Control and Attention Test (continuous performance task), and medical record diagnoses of ASD and ADHD. Mixed linear and log-binomial regression models estimated treatment effects. Subgroup analyses examined effects by sex, birthweight, family income, dietary omega-3 intake, and blood omega-3 status. Results At least 1 outcome measure was available for all 376 children eligible for follow-up. Flanker scores were higher (better) for the DHA+AA group (difference=3.02; 95% CI=0.01, 6.04), particularly among children with lower dietary omega-3 intake (difference=4.88; 95% CI=0.53, 9.23). DHA+AA was associated with fewer teacher-rated attention problems among children with birthweight>1500g (difference=-2.97; 95% CI=-5.38, -0.55). No group differences were found in likelihood of autism and ADHD diagnoses. Conclusions DHA+AA supplementation was associated with modest improvements in attention, particularly among specific subgroups, supporting further investigation of targeted, personalized nutrition approaches. There was no association between supplementation and likelihood of ADHD and autism. Clinical Trial Registration ClinicalTrials.gov Identifier: NCT05191823

Authors

Institutions

Publication Details

Journal
Journal of Autism and Developmental Disorders
Published
2026-10-22
DOI
https://doi.org/10.1007/s10803-026-07566-z
Primary Topic
Fatty Acid Research and Health
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Fatty Acid Supplementation in Toddlers Born Preterm and Attention and Autism Outcomes at 8–10 Years: Omega Tots Randomized Controlled Trial Long-Term Follow-Up

Sarah A. Keim, Lisa M. Robinette, Mark A. Klebanoff, Christopher W. Bartlett et al.
Journal of Autism and Developmental Disorders
Fatty Acid Research and Health
article

Fatty Acid Supplementation in Toddlers Born Preterm and Attention and Autism Outcomes at 8–10 Years: Omega Tots Randomized Controlled Trial Long-Term Follow-Up

Sarah A. Keim, Lisa M. Robinette, Mark A. Klebanoff, Christopher W. Bartlett, Kelly M. Boone, Lynette K. Rogers, Joseph Rausch, H. Gerry Taylor
article en

Abstract

Abstract Purpose Children born preterm are at increased likelihood of autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD). We examined whether 6 months of daily dietary docosahexaenoic acid (DHA) + arachidonic acid (AA) supplementation at age 1-year reduced attention problems and likelihood of ADHD and ASD diagnoses in children born preterm. Methods In the Omega Tots randomized placebo-controlled trial, children born at <35 weeks’ gestation received daily DHA (200 mg) + AA (200 mg) or placebo (400 mg corn oil) at 10–16 months’ corrected age. This long-term follow-up assessed outcomes at 8.5–10.5 years. Outcomes included parent- and teacher-rated attention problems, performance on the Flanker Inhibitory Control and Attention Test (continuous performance task), and medical record diagnoses of ASD and ADHD. Mixed linear and log-binomial regression models estimated treatment effects. Subgroup analyses examined effects by sex, birthweight, family income, dietary omega-3 intake, and blood omega-3 status. Results At least 1 outcome measure was available for all 376 children eligible for follow-up. Flanker scores were higher (better) for the DHA+AA group (difference=3.02; 95% CI=0.01, 6.04), particularly among children with lower dietary omega-3 intake (difference=4.88; 95% CI=0.53, 9.23). DHA+AA was associated with fewer teacher-rated attention problems among children with birthweight>1500g (difference=-2.97; 95% CI=-5.38, -0.55). No group differences were found in likelihood of autism and ADHD diagnoses. Conclusions DHA+AA supplementation was associated with modest improvements in attention, particularly among specific subgroups, supporting further investigation of targeted, personalized nutrition approaches. There was no association between supplementation and likelihood of ADHD and autism. Clinical Trial Registration ClinicalTrials.gov Identifier: NCT05191823

Journal of Autism and Developmental Disorders
Nationwide Children's Hospital (US), Abigail Wexner Research Institute (US), The Ohio State University (US)
Openalex Percentile: Top 13%
Fatty Acid Research and Health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon